Overview

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
0
Participant gender:
Male
Summary
Identify exosomal micro RNA that predict responses to ADT
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Medical College of Wisconsin
Treatments:
Androgens
Ascorbic Acid
Bicalutamide
Docetaxel
Estrogens, Conjugated (USP)
Goserelin
Leuprolide
Methyltestosterone
Triptorelin Pamoate
Criteria
Inclusion Criteria:

- Histologically proven prostate cancer.

- Testosterone level >30ng/ml and at least 6 months since last dose of hormonal therapy.

- History/physical examination including a detailed description of the stage of prostate
cancer within 8 weeks prior to registration.

- CT scan of abdomen and pelvis with IV contrast and bone scan should be performed
within 8 weeks prior to registration.

- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.

- Age ≥ 18.

- Patients must provide study-specific informed consent prior to study entry for this
project and mandatory blood specimen for banking for future studies (future studies
may include genetic testing).

Exclusion Criteria:

- Received hormonal therapy less than 6 months prior to registration.

- History of active secondary malignancy.

- Decline hormone therapy for prostate cancer.

- Current or previous treatment with 5-alpha reductase inhibitors within 6 months prior
to enrollment.